Modality
Vaccine
MOA
PD-L1i
Target
GLP-1R
Pathway
Checkpoint
Asthma
Development Pipeline
Preclinical
Jul 2024
→ Jun 2031
PreclinicalCurrent
NCT07150910
1,791 pts·Asthma
2024-07→2031-06·Not yet recruiting
1,791 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-195.2y awayInterim· Asthma
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Not yet…
Catalysts
Interim
2031-06-19 · 5.2y away
Asthma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07150910 | Preclinical | Asthma | Not yet recr... | 1791 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Mavuglumide | Bayer | Approved | GLP-1R |